Zuckerberg San Francisco General Hospital
San Francisco, California, 94110, United States
Location status: Recruiting
Location contact
Edilberto Amorim, MD
CONTACT
NCT Number: NCT05851391
RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2
San Francisco, California, 94110, United States
Location status: Recruiting
Edilberto Amorim, MD
CONTACT
Rationale: Seizures emerge as a complication of hypoxic-ischemic brain injury in near a third of patients successfully resuscitated from cardiac arrest. Seizures post-cardiac arrest can be refractory to treatment with anti-seizure medications and anesthetics may be used for refractory status epilepticus control. Anesthetic treatment guided by continuous EEG can target burst suppression or seizure suppression, however it is not known which strategy is superior for achieving PCARSE control.
Objective: determine the safety and feasibility of post-cardiac arrest refractory status epilepticus (PCARSE) treatment using EEG goals for intravenous anesthetic titration (burst suppression vs. seizure suppression).
Clinical Trial Phase: II
Study Design: prospective, randomized, open-label, blinded end-point, concurrently-controlled, parallel arms design clinical trial.
Study Period: two years
Study Population: unconscious cardiac arrest survivors with return of spontaneous circulation who develop post-cardiac arrest refractory status epilepticus (PCARSE).
Interventions: anesthetic use targeting burst suppression vs. seizure suppression on EEG for 24 hours. Intervention maybe repeated using the dame EEG target once in case of PCARSE recurrence.
Sample Size: 30 subjects randomized in a 1:1 ratio to either burst suppression or seizure suppression EEG targets.
Primary Endpoints: Safety and feasibility of seizure control using burst suppression or seizure suppression EEG targets for PCARSE treatment.
Secondary Endpoints: Seizure recurrence incidence, time to seizure recurrence, number and dose of anti-seizure medication and anesthetic needed for PCARSE control, Death or disability according to the Cerebral Performance Category at Discharge (30 days), and Death or disability according to the modified Rankin Scale at Discharge (30 days).
Risks: Participants receiving anesthetics for PCARSE treatment will be monitored for hypotension, propofol infusion syndrome, and hypertriglyceridemia. Patients with PCARSE are at high risk for death and prolonged hospital stays.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
EEG monitoring within 7 days from ROSC
Exclusion criteria
The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
Time frame: 48 hours
Continuous EEG will be monitored to determine time to PCARSE recurrence during the anesthetic maintenance and anesthetic weaning phase (combined)
Time frame: 24-48 hours
Presence of seizures on EEG after initiation of anesthetic maintenance phase
Time frame: 30 days
Cerebral Performance Category score at Discharge
Time frame: 30 days
modified Rankin Scale score at Discharge
Time frame: 90 days
Cerebral Performance Category score at 90 days
Time frame: 90 days
modified Rankin Scale score at Discharge
Time frame: 180 days
modified Rankin Scale score at Discharge
Time frame: 180 days
modified Rankin Scale score at Discharge
Time frame: 24-48 hours
Number of anti-seizure medications and anesthetics used for PCARSE control after initiation of anesthetic maintenance phase and prior to weaning
Time frame: 24-48 hours
Presence of seizures on EEG after initiation of anesthetic weaning phase
Time frame: 24-48 hours
Dose of anti-seizure medications and anesthetics used for PCARSE control after initiation of anesthetic maintenance phase and prior to weaning
Contact information is provided by the study sponsor or research team.
Edilberto Amorim, MD
CONTACT
Kevin Bao
CONTACT
University of California, San Francisco
Other
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest (RESTORE)
Acronym: RESTORE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06048796
Brain Diseases, Brain Ischemia
Arnhem, Gelderland, Netherlands
View Trial DetailsNCT04198792
Brain Diseases, Brain Ischemia
Gothenburg, Sweden
View Trial DetailsNCT03112486
Brain Anoxia Ischemia, Brain Diseases
Gainesville, Florida, United States
View Trial DetailsNCT05376267
Body Temperature Changes, Brain Diseases
Birmingham, Alabama, United States
View Trial Details